SAN DIEGO & SHANGHAI, January 18, 2021 — BioDuro-Sundia received the “2020 EXCELLENT Team Service” award from Lynk Pharmaceuticals, as recognition of the efforts and contributions made by the BioDuro-Sundia drug discovery Chemistry team.
The Lynk project was led by Dr. Wang Feng in BioDuro-Sundia’s Chemistry Department. The whole team was recognized by Lynk for their efficient working attitude and excellent coordination to advance Lynk’s drug discovery programs.
“Dr. Wang Feng has deep experience in synthetic planning and optimization. His Chemistry team has provided rapid and professional services,” said Dr. Li Xiaodong, Director of Lynk’s project. “We started this work together with Sundia. We are now very glad to hear about the integration of BioDuro and Sundia which can now offer partners broader scope of services and support. We look forward to a long and friendly relationship with the combined BioDuro-Sundia.”
Dr. Chen Jiong, Head of Chemistry at Sundia, said, “Thanks for the full trust from Lynk. This award is a great recognition for us. We will continuously provide the highest quality service to Lynk and other customers.”
Mr. Lei Zhenhan, Director of Business Development at BioDuro-Sundia, said, “We are very glad to have excellent cooperation with Lynk. Lynk is a fast-growing company. And we are looking forward to continuing to support Lynk as their programs advance, by leveraging our comprehensive drug discovery & development services, including our brand new research center in Wuxi City.”
About Lynk Pharmaceuticals
Lynk Pharmaceuticals is a clinical stage company. It was founded in 2018 by seniordrug discovery experts and executives from Pfizer, Merck and Johnson &Johnson. Driven by a higher purpose, Lynk Pharmaceuticals aims to be a marketleader in addressing unmet medical needs through the development of innovativetherapies in the fields of oncology, autoimmune and inflammation. Lynk Pharmaceuticals is positioned to become a global company with successful trackof record for external collaboration, as evidenced by an out-licensing dealwith a US partner (close to 200 million dollars upfront and milestone payments,plus an up to a double-digit royalty payment) and in-licensing deal with KobeUniversity and RIKEN of Japan on the RAS program.
Sinceits inception, it has won several awards and honors, including the First PlaceWinner in China National Innovation & Entrepreneurship Competition in 2018,Frost & Sullivan China New Economy Award – Excellence in Innovation in2019, and Company with the Most Growth Potentials Award by the QiantangDistrict, Zhejiang, in 2020.
BioDuro-Sundia, an Advent International portfolio company, is a leading global life sciences research and development organization that provides biopharmaceutical clients and partners with comprehensive, fully integrated drug discovery and development services, from lead development to IND submission to GMP manufacture of drug product. The company is the industry’s third largest CRDMO (contract research, development and manufacturing organizations) with major operations in China and the US—featuring more than 2,000 employees and 10 global sites.
Core expertise includes small and large molecule discovery, development and scale up, combined with unique technology platforms such as bioavailability enhancement of insoluble compounds. The ‘one-stop-shop’ operation helps biopharma partners significantly accelerate discovery and de-risk development to create higher value outcomes.